Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Completed 2Terminated 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Polycystic Ovary Syndrome 2Insulin Resistance 2Inflammation 2Hyperandrogenism 2Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Anovulation 1

Interventions

Cyclophosphamide 2042Radiotherapy 1859Cisplatin 1825Carboplatin 1533Gemcitabine 1434Paclitaxel 1289Bevacizumab 1270Docetaxel 1202pembrolizumab 1198Oxaliplatin 1160Capecitabine 1142Fluorouracil 1061Dexamethasone 971Rituximab 919Nivolumab 908Magnetic Resonance Spectroscopy 862Etoposide 839Doxorubicin 823Drug Therapy 792Radiosurgery 776Irinotecan 775Cytarabine 736fludarabine 716Leucovorin 676Lenalidomide 608fludarabine phosphate 564Temozolomide 552Radiation 541Filgrastim 540Cetuximab 537

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × Interventional × salicylsalicylic acid × Clear all
NCT03229408 2025-06-10

TIN-PCOS-AOD

University of Illinois at Chicago

Phase 2 Completed
60 enrolled 28 charts

Anovulation, Inflammation, Insulin Resistance, Polycystic Ovary Syndrome, Hyperandrogenism

NCT04146038 2023-05-24

Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease

Rutgers, The State University of New Jersey

Phase 2 Completed
5 enrolled 9 charts
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT01489319 2017-02-10

ELI-ROAS

Indiana University

Phase 1 Terminated
47 enrolled

Inflammation, Insulin Resistance, Polycystic Ovary Syndrome, Hyperandrogenism

Data powered by HemOnc (CC BY 4.0) Colophon âš¡